We are live on ! Find out more
ALXA

Alexza Pharmaceuticals Inc
ALXA

Delisted

ALXA was delisted on the 16th of June, 2016.

41 hedge funds and large institutions have $30.6M invested in Alexza Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

835% more call options, than puts

Call options by funds: $6.77M | Put options by funds: $724K

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

48% more capital invested

Capital invested by funds: $20.7M → $30.6M (+$9.87M)

37% more funds holding

Funds holding: 3041 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
41
Holders Change
+11
Holders Change %
+36.67%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
12
Reduced
6
Closed
2
Calls
$6.77M
Puts
$724K
Net Calls
+$6.04M
Net Calls Change
-$275K
Name Holding Trade Value Shares
Change
Change in
Stake
LPA
1
Lansdowne Partners Austria
Austria
$6.94M +$671K +142,700 +12%
CS
2
Credit Suisse
Switzerland
$4M +$596K +126,715 +19%
Morgan Stanley
3
Morgan Stanley
New York
$3.53M +$1.91M +404,899 +142%
Federated Hermes
4
Federated Hermes
Pennsylvania
$3.45M
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.15M +$311K +66,050 +19%
VM
6
VHCP Management
New York
$2.05M
KCM
7
Kennedy Capital Management
Missouri
$1.8M +$494K +105,000 +43%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$816K +$657K +139,676 +705%
FAM
9
Fortaleza Asset Management
Illinois
$744K +$684K +145,283 New
BIT
10
BlackRock Institutional Trust
California
$714K +$656K +139,489 New
BCM
11
BBT Capital Management
Texas
$604K -$68.2K -14,500 -11%
OAM
12
Oxford Asset Management
United Kingdom
$549K +$504K +107,205 New
HHMI
13
Howard Hughes Medical Institute
Maryland
$506K
Goldman Sachs
14
Goldman Sachs
New York
$382K -$11.3K -2,399 -3%
Group One Trading
15
Group One Trading
Illinois
$284K +$261K +55,452 New
BFA
16
BlackRock Fund Advisors
California
$282K +$90.1K +19,148 +53%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$268K +$226 +48 +0.1%
BCM
18
Bridgeway Capital Management
Texas
$256K +$235K +50,000 New
Northern Trust
19
Northern Trust
Illinois
$144K +$2.01K +428 +2%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$138K
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$135K
Nomura Holdings
22
Nomura Holdings
Japan
$127K -$1.41K -300 -1%
Jane Street
23
Jane Street
New York
$111K +$102K +21,629 New
DS
24
DRW Securities
Illinois
$103K +$94.1K +20,000 New
U
25
UBS
Switzerland
$87K -$62.1K -13,191 -44%

ALXA Hedge Fund Activity: Q3 2013 in Review

41 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Alexza Pharmaceuticals Inc (ALXA) for Q3 2013, worth a combined $30.6M — up 48% from $20.7M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ALXA positions and 2 closed out — a net gain of 12 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.91M. The largest seller was Lansdowne Partners Limited Partnership, exiting entirely with an estimated $1.33M sold.

  • 41 institutional investors held Alexza Pharmaceuticals Inc (ALXA) as of Q3 2013, up from 30 in Q2 2013.
  • Funds reported $30.6M of Alexza Pharmaceuticals Inc stock for Q3 2013, up 48% quarter-over-quarter.
  • 14 funds opened new Alexza Pharmaceuticals Inc positions in Q3 2013 and 2 closed out, a net change of +12 holders.
  • The largest Alexza Pharmaceuticals Inc buyer in Q3 2013 was Morgan Stanley, an estimated $1.91M added.
  • The largest Alexza Pharmaceuticals Inc seller in Q3 2013 was Lansdowne Partners Limited Partnership, an estimated $1.33M sold.

Based on aggregated 13F filings for Q3 2013.